Drugs / BI 1584862
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07336758 | Jan → Mar 2026 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06957756 | Aug 2025 → May 2026 | liver disorder | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06148948 | Dec 2023 → May 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06041438 | Sep → Nov 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06006598 | Aug 2023 → May 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05520827 | Sep 2022 → Mar 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06769048 | Jan 2025 → Feb 2027 expected | diffuse secondary choroid atrophy | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1584862 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05520827 ↗ |
| Route | Oral | “following oral administration” NCT05520827 ↗ |